Pancreatic Cancer Metastatic
Also known as: Pancreatic Cancer Metastatic / Metastatic Pancreatic cancer / Metastatic Pancreatic Cancers / Pancreatic carcinoma metastatic / Metastases to pancreas / Malignant neoplasm of pancreas metastatic / Pancreas neoplasm malignant metastatic / Pancreatic metastasis
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB01101 | Capecitabine | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. |
| DB00530 | Erlotinib | Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders. |